Clinical Trial Update: Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19 [Phase 3]

View source ↗

Summary

Phase 3 study evaluating lenzilumab for efficacy and safety in COVID-19 pneumonia is ongoing but status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Disease 2019 Pneumonia

Drugs mentioned

• Lenzilumab (lenzilumab)

Snippet

Sponsor: Humanigen, Inc. | Conditions: Coronavirus Disease 2019 (COVID-19) Pneumonia | Phase 3 | Status: UNKNOWN